Patents by Inventor José Manuel Bartolomé-Nebreda
José Manuel Bartolomé-Nebreda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230099293Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: December 18, 2020Publication date: March 30, 2023Applicant: JANSSEN PHARMACEUTICA NVInventors: José Manuel BARTOLOMÉ-NEBREDA, Petrus Jacobus Johannes Antonius BUIJNSTERS, Ana Isabel DE LUCAS OLIVARES, Joseph Elisabeth LEENAERTS, Carolina MARTINEZ LAMENCA, Daniel OEHLRICH, Andrés Avelino TRABANCO-SUÁREZ, Yves Emiel M VAN ROOSBROECK, Adriana Ingrid VELTER
-
Publication number: 20230058733Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.Type: ApplicationFiled: December 18, 2020Publication date: February 23, 2023Applicant: JANSSEN PHARMACEUTICA NVInventors: José Manuel BARTOLOMÉ-NEBREDA, Petrus Jacobus Johannes Antonius BUIJNSTERS, Joseph Elisabeth LEENAERTS, Carolina MARTINEZ LAMENCA, Daniel OEHLRICH, Andrés Avelino TRABANCO-SUÁREZ, Yves Emiel M VAN ROOSBROECK, Adriana Ingrid VELTER
-
Publication number: 20210300943Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: June 20, 2019Publication date: September 30, 2021Inventors: José Manuel Bartolomé-Nebreda, Andrés Avellno Trabanco-Suárez, Carlos Manuel Martinez-Viturro, Francisca Deigado-Jiménez, Susana Coride-Ceide, Juan Antonio Vega Ramiro
-
Publication number: 20210300900Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: June 20, 2019Publication date: September 30, 2021Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Francisca Delgado-Jiménez, Ana Isabel De Lucas Olivares, Juan Antonio Vega Ramiro
-
Publication number: 20210277003Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: June 20, 2019Publication date: September 9, 2021Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Carolina Martinez Lamenca, Joseph Elisabeth Leenaerts, Daniel Oehlrich, Petrus Jacobus Johannes Antonius Buijnsters, Adriana Ingrid Velter, Yves Emiel Maria Van Roosbroeck
-
Publication number: 20210277015Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: June 20, 2019Publication date: September 9, 2021Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Carlos Manuel Martinez-Viturro, Francisca Delgado-Jiménez, Susana Conde-Ceide, Juan Antonio Vega Ramiro
-
Publication number: 20210261527Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: June 20, 2019Publication date: August 26, 2021Inventors: José Manuel Bartolomé-Nebreda, Andres Avellno Trabanco-Suarez, Carlos Manuel Martinez-Viturro
-
Publication number: 20210130352Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: June 20, 2019Publication date: May 6, 2021Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Joseph Elisabeth Leenaerts, Daniel Oehlrich, Petrus Jacobus Johannes Antonius Buijnsters, Carolina Martinez Lamenca, Adriana Ingrid Velter, Yves Erniel Maria Van Roosbroeck
-
Publication number: 20210122763Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: June 20, 2019Publication date: April 29, 2021Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Ana Isabel De Lucas Olivares, Francisca Delgado-Jiménez, Susana Conde-Ceide, Juan Antonio Vega Ramiro
-
Publication number: 20210115040Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: June 20, 2019Publication date: April 22, 2021Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Ana Isabel De Lucas Olivares, Gary John Tresadern, Susana Conde-Ceide
-
Publication number: 20200157092Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: February 27, 2018Publication date: May 21, 2020Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Manuel Jesús Alcázar-Vaca
-
Publication number: 20200079766Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: December 15, 2017Publication date: March 12, 2020Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Carlos Manuel Martinez Viturro, Gary John Tresadem, Manuel Jesús Alcázar-Vaca, Wei Zhang, Gang Chen
-
Publication number: 20200048267Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: February 6, 2018Publication date: February 13, 2020Applicant: Janssen Pharmaceutica NVInventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Carlos Manuel Martinez Viturro
-
Publication number: 20190359609Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.Type: ApplicationFiled: December 15, 2017Publication date: November 28, 2019Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Carlos Manuel Martinez Viturro, Gary John Tresadern, Manuel Jesús Alcázar-Vaca
-
Patent number: 9550784Abstract: The present invention relates to novel imidazo[1,2-b]pyridazine and imidazo[1,2-a]-pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which may be useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.Type: GrantFiled: July 8, 2013Date of Patent: January 24, 2017Assignee: Beerse Pharmaceutica NVInventors: Laurent Christian L. Leclercq, José Manuel Bartolomé-Nebreda, Susana Conde-Ceide, Michiel Luc Maria Van Gool
-
Patent number: 9422296Abstract: The present invention relates to 4-aryl-6-piperazin-1-yl-3-substituted-pyridazines that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.Type: GrantFiled: July 28, 2014Date of Patent: August 23, 2016Assignee: JANSSEN PHARMACEUTICA NVInventors: Gregor James Macdonald, Xavier Jean Michel Langlois, José Manuel Bartolomé-Nebreda, Michiel Luc Maria Van Gool
-
Patent number: 9255103Abstract: In one aspect, the invention relates to substituted pyrazolo[1,5-a]pyrazines analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: March 27, 2014Date of Patent: February 9, 2016Assignee: Vanderbilt UniversityInventors: P. Jeffrey Conn, Craig W. Lindsley, Shaun R. Stauffer, José Manuel Bartolomé-Nebreda, Susana Conde-Ceide, Gregor Macdonald, Han Min Tong, Carrie K. Jones
-
Publication number: 20150216863Abstract: In one aspect, the invention relates to substituted bicyclic alkoxy pyrazole analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: April 3, 2015Publication date: August 6, 2015Inventors: P. Jeffrey Conn, Craig W. Lindsley, Shaun R. Stauffer, José Manuel Bartolomé-Nebreda, Susana Conde-Ceide, Gregor James Macdonald, Han Min Tong, Manuel Jesús Alcázar-Vaca, José Ignacio Andrés-Gil, Miguel Angel Pena-Piñón
-
Patent number: 9090632Abstract: In one aspect, the invention relates to novel bicyclic oxazole and thiazole compounds which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (“mGluR5”); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions; and methods for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: August 31, 2011Date of Patent: July 28, 2015Assignee: Vanderbilt UniversityInventors: P. Jeffrey Conn, Craig W. Lindsley, Shaun R. Stauffer, Carrie K. Jones, Jose Manuel Bartolome-Nebreda, Susana Conde-Ceide, Gregor James Macdonald, Manuel Jesus Alcazar Vaca
-
Publication number: 20150203498Abstract: The present invention relates to novel imidazo[1,2-b]pyridazine and imidazo[1,2-a]-pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which may be useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.Type: ApplicationFiled: July 8, 2013Publication date: July 23, 2015Applicant: JANSSEN PHARMACEUTICA NVInventors: Laurent Christian L. Leclercq, José Manuel Bartolomé-Nebreda, Susana Conde-Ceide, Michiel Luc Maria Van Gool